NASDAQ:REVB Revelation Biosciences Q3 2025 Earnings Report $1.08 +0.05 (+4.33%) As of 02:41 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Revelation Biosciences EPS ResultsActual EPS-$7.08Consensus EPS -$5.36Beat/MissMissed by -$1.72One Year Ago EPSN/ARevelation Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARevelation Biosciences Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time7:00AM ETUpcoming EarningsRevelation Biosciences' Q2 2026 earnings is estimated for Friday, August 7, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Revelation Biosciences Earnings HeadlinesRevelation Biosciences, Inc.: Revelation Biosciences Announces Adoption of Stockholder Rights PlanJuly 10, 2026 | finanznachrichten.deREVB Poised for Big YearMay 8, 2026 | finance.yahoo.comConfirm Your Name Before the Letter Goes OutAmericans who believe in real retirement protection are adding their names to a statement going out to Washington and Wall Street. It's a message that people are fed up with inflation and the erosion of their savings. President Trump took a stand on protecting American wealth. Now you can add your voice while also learning how to move part of your IRA or 401(k) into physical gold and silver, tax and penalty free.July 15 at 1:00 AM | American Alternative (Ad)Revelation Biosciences (REVB) price target decreased by 37.65% to 54.06March 28, 2026 | msn.comRevelation Biosciences (REVB) price target increased by 300.00% to 86.70February 4, 2026 | msn.comREVB Comes to Agreement with FDAJanuary 29, 2026 | finance.yahoo.comSee More Revelation Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Revelation Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revelation Biosciences and other key companies, straight to your email. Email Address About Revelation BiosciencesRevelation Biosciences (NASDAQ:REVB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.View Revelation Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Johnson & Johnson’s Earnings Dip Looks Like a Buying OpportunityApple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before EarningsWhy ASML’s AI Monopoly Is Still Getting StrongerAlphabet’s AI Spending Question Looms Over Q2 EarningsCPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive StocksPlot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-MergerMarriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Upcoming Earnings GE Aerospace (7/16/2026)Taiwan Semiconductor Manufacturing (7/16/2026)Netflix (7/16/2026)Prologis (7/16/2026)State Street (7/16/2026)U.S. Bancorp (7/16/2026)Abbott Laboratories (7/16/2026)Intuitive Surgical (7/16/2026)UnitedHealth Group (7/16/2026)Fifth Third Bancorp (7/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
